(Q35968748)

11 August 2017

1 reference

title

First-line therapy for ovarian carcinoma: what's next? (English)

1 reference

11 August 2017

1 reference

Tate Thigpen

1

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

22 Suppl 2

1 reference

11 August 2017

page(s)

21-28

1 reference

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030115

21 January 2018

Identifiers

DOI

10.1081/CNV-200030115

1 reference

11 August 2017

1 reference